menu search

TXG / 10x Genomics: Unveiling The Investment Potential

10x Genomics: Unveiling The Investment Potential
10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has a huge growth opportunity in the genomics market thanks to its razor-blade business model and innovative product roadmap. Read More
Posted: Nov 4 2023, 01:02
Author Name: Seeking Alpha
Views: 052174

TXG News  

10x Genomics: Unveiling The Investment Potential

By Seeking Alpha
November 4, 2023

10x Genomics: Unveiling The Investment Potential

10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenu more_horizontal

10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor more_horizontal

10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
November 2, 2023

10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth more_horizontal

10x Genomics: Recent Performance Amplifies My Bullish Conviction

By Seeking Alpha
September 8, 2023

10x Genomics: Recent Performance Amplifies My Bullish Conviction

10x Genomics reported impressive Q2 performance with revenue growing by 28% YoY to reach $147M. The company's growth is driven by strong performance i more_horizontal

10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say

By Zacks Investment Research
August 3, 2023

10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be w more_horizontal

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 3, 2023

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of more_horizontal

Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation

By 24/7 Wall Street
July 14, 2023

Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation

Fintel reports that on July 13, 2023, Goldman Sachs maintained coverage of 10x Genomics Inc – (TXG) with a Sell recommendation. more_horizontal

10x Genomics: Growth Outweighing The Risks

By Seeking Alpha
June 24, 2023

10x Genomics: Growth Outweighing The Risks

10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics more_horizontal


Search within

Pages Search Results: